Get the Stockscreener App
1.3418
2.43%
+0.0318
Artelo Biosciences Inc stock is currently priced at $1.3418, with a 24-hour trading volume of 5,411.
It has seen a +2.43% increased in the last 24 hours and a -11.72% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.30 pivot point. If it approaches the $1.35 resistance level, significant changes may occur.
Previous Close:
$1.31
Open:
$1.31
24h Volume:
5,411
Market Cap:
$4.33M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-0.4042
EPS:
-3.32
Net Cash Flow:
$-8.21M
1W Performance:
+2.04%
1M Performance:
-11.72%
6M Performance:
-6.17%
1Y Performance:
-50.12%
1D Range:
$1.28
$1.3418
52W Range:
$1.15
$2.98
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858 925 7049
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
GlobeNewswire Inc.
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
GlobeNewswire Inc.
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
GlobeNewswire Inc.
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
GlobeNewswire Inc.
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
GlobeNewswire Inc.
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
GlobeNewswire Inc.
Artelo Biosciences Inc Stock (ARTL) Financials Data
Artelo Biosciences Inc (ARTL) Net Income 2024
ARTL net income (TTM) was -$9.29 million for the quarter ending December 31, 2023, a +7.87% increase year-over-year.
Artelo Biosciences Inc (ARTL) Cash Flow 2024
ARTL recorded a free cash flow (TTM) of -$8.21 million for the quarter ending December 31, 2023, a -2.49% decrease year-over-year.
Artelo Biosciences Inc (ARTL) Earnings per Share 2024
ARTL earnings per share (TTM) was -$3.14 for the quarter ending December 31, 2023, a +12.04% growth year-over-year.
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
3.69%
0.93%
Cap:
|
Volume (24h):